Pegintron(peginterferon alfa-2b)
PegIntron, PegIntron/ Rebetol Combo Pack, Sylatron, ViraferonPeg (peginterferon alfa-2b) is a protein pharmaceutical. Peginterferon alfa-2b was first approved as Pegintron on 2000-05-24. It is used to treat brain neoplasms, chronic hepatitis c, colorectal neoplasms, cryoglobulinemia, and essential thrombocythemia amongst others in the USA. It has been approved in Europe to treat chronic hepatitis c. The pharmaceutical is active against interferon alpha/beta receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 1 more
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Peginterferon alfa-2b
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Pegintron | peginterferon alfa-2b | Merck & Co | N-103949 DISCN | 2001-01-19 | 1 products |
| Sylatron | peginterferon alfa-2b | Merck & Co | N-103949 DISCN | 2011-03-29 | 3 products |
| Pegintron | peginterferon alfa-2b | Merck & Co | N-103949 DISCN | 2001-01-19 | 7 products |
Hide discontinued
Peginterferon alfa-2b
+
Ribavirin
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| PegIntron/ Rebetol Combo Pack | peginterferon alfa-2b and ribavirin | Merck & Co | N-125196 DISCN | 2008-06-13 | 4 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Show 16 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
365 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis | D006505 | — | K75.9 | 9 | 42 | 61 | 44 | 63 | 208 |
| Hepatitis c | D006526 | — | B19.2 | 10 | 44 | 70 | 34 | 56 | 202 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 9 | 39 | 52 | 40 | 59 | 188 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 7 | 33 | 58 | 25 | 49 | 163 |
| Chronic hepatitis | D006521 | — | K73.9 | 6 | 18 | 19 | 16 | 11 | 66 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 3 | 4 | 12 | 16 | 14 | 47 |
| Hepatitis b | D006509 | — | — | 3 | 3 | 7 | 13 | 16 | 40 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 4 | 10 | 7 | 4 | 3 | 26 |
| Infections | D007239 | EFO_0000544 | — | — | 5 | 4 | 4 | 4 | 17 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 3 | 9 | 1 | 2 | 13 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 9 | 12 | 4 | — | 2 | 23 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 2 | 8 | 3 | — | — | 12 |
| Leukemia | D007938 | — | C95 | 2 | 7 | 1 | — | — | 10 |
| Neoplasms | D009369 | — | C80 | 5 | 1 | 1 | — | 1 | 8 |
| Coinfection | D060085 | — | — | 1 | 3 | 3 | — | 1 | 7 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 5 | 1 | — | — | 7 |
| Polycythemia vera | D011087 | — | D45 | 1 | 1 | 4 | — | — | 5 |
| Polycythemia | D011086 | EFO_0005804 | D75.1 | 1 | 1 | 4 | — | — | 5 |
| Essential thrombocythemia | D013920 | — | D47.3 | — | 3 | 2 | — | — | 5 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 1 | 2 | 1 | — | — | 4 |
Show 18 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 4 | 6 | — | — | — | 7 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | 3 | — | — | — | 4 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 3 | — | — | — | 4 |
| Neurofibroma | D009455 | EFO_0000622 | — | 1 | 2 | — | — | — | 3 |
| Glioma | D005910 | EFO_0000520 | — | — | 3 | — | — | — | 3 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | — | 2 | — | — | 1 | 3 |
| Neurofibromatoses | D017253 | — | Q85.00 | — | 2 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 2 | — | — | — | 2 |
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | 2 | — | — | — | 2 |
| Fallopian tube neoplasms | D005185 | — | — | 2 | 1 | — | — | — | 2 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 2 | 2 |
| Virus diseases | D014777 | — | B34 | — | — | — | — | 2 | 2 |
| Intravenous substance abuse | D015819 | — | — | — | — | — | — | 1 | 1 |
| Social behavior | D012919 | — | STY/T054 | — | — | — | — | 1 | 1 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 1 | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | — | — | 1 | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 1 | 1 |
| Follicular lymphoma | D008224 | — | C82 | — | — | — | — | 1 | 1 |
| Up-regulation | D015854 | — | — | — | — | — | — | 1 | 1 |
| Immunotherapy | D007167 | — | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Peginterferon alfa-2b |
| INN | peginterferon alfa-2b |
| Description | Interferon alpha-2 precursor (Interferon alpha-A) (LeIF A) |
| Classification | Protein |
| Drug class | PEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201561 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00022 |
| UNII ID | G8RGG88B68 (ChemIDplus, GSRS) |
Target
Agency Approved
IFNAR1
IFNAR1
Organism
Homo sapiens
Gene name
IFNAR1
Gene synonyms
IFNAR
NCBI Gene ID
Protein name
interferon alpha/beta receptor 1
Protein synonyms
alpha-type antiviral protein, beta-type antiviral protein, CRF2-1, Cytokine receptor class-II member 1, Cytokine receptor family 2 member 1, IFN-alpha/beta receptor 1, IFN-R-1, IFNalpha/beta receptor 1, interferon (alpha, beta and omega) receptor 1, interferon receptor 1, interferon-alpha/beta receptor alpha chain, interferon-beta receptor 1, Type I interferon receptor 1
Uniprot ID
Mouse ortholog
Ifnar1 (15975)
interferon alpha/beta receptor 1 (Q80UJ3)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,202 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
27,863 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use